First Commonwealth Financial Corp PA Sells 1,500 Shares of DexCom, Inc. (NASDAQ:DXCM)

First Commonwealth Financial Corp PA lowered its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 14.6% during the third quarter, HoldingsChannel reports. The firm owned 8,800 shares of the medical device company’s stock after selling 1,500 shares during the quarter. First Commonwealth Financial Corp PA’s holdings in DexCom were worth $590,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Migdal Insurance & Financial Holdings Ltd. bought a new stake in DexCom in the second quarter valued at approximately $25,000. Sachetta LLC raised its holdings in DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 171 shares during the period. DT Investment Partners LLC lifted its position in DexCom by 492.2% during the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after acquiring an additional 315 shares during the last quarter. Riverview Trust Co boosted its holdings in shares of DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after acquiring an additional 232 shares during the period. Finally, ORG Partners LLC increased its stake in shares of DexCom by 1,992.0% during the second quarter. ORG Partners LLC now owns 523 shares of the medical device company’s stock worth $59,000 after purchasing an additional 498 shares during the period. 97.75% of the stock is owned by institutional investors.

DexCom Price Performance

DXCM traded down $0.05 on Wednesday, reaching $77.89. The stock had a trading volume of 82,766 shares, compared to its average volume of 3,923,074. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The company has a market capitalization of $30.42 billion, a price-to-earnings ratio of 46.67, a price-to-earnings-growth ratio of 2.38 and a beta of 1.17. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The firm has a 50-day moving average of $70.94 and a 200-day moving average of $88.58.

Insider Activity

In related news, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This trade represents a 0.56 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. The trade was a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,431 shares of company stock valued at $399,319 over the last quarter. 0.30% of the stock is owned by company insiders.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Stifel Nicolaus boosted their price target on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, August 23rd. Piper Sandler reiterated an “overweight” rating and issued a $90.00 price objective on shares of DexCom in a research note on Monday, August 26th. Robert W. Baird increased their target price on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, August 5th. Oppenheimer dropped their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Finally, Raymond James reduced their price target on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $104.59.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.